|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Most notably, inducible knockdown of LIMK2 fully reverses CRPC tumorigenesis in castrated mice, underscoring its potential as a clinical target for CRPC.
|
30716360 |
2019 |
|
Carcinogenesis
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
As the mechanisms of LIMK-associated tumorigenesis are still unclear, we analyzed the tumorigenic functions of LIM kinase 2 (LIMK2) in human bladder cancer (BC) and explored whether the newly identified LIMK2 3´-UTR SNP rs2073859 (G-to-A allele) is correlated with clinical features.
|
30006972 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
We also identified TWIST1 as a direct substrate of LIMK2, which uncovered the molecular mechanism of LIMK2-induced malignancy.
|
30716360 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Limk2 deletion increased colon tumour size in a colitis-associated colorectal mouse cancer model.
|
23585469 |
2014 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Limk2 deletion increased colon tumour size in a colitis-associated colorectal mouse cancer model.
|
23585469 |
2014 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
LIMK2 inhibition or ablation is therefore an alternative approach for modulating Aurora A deregulation in cancer.
|
22492986 |
2012 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Most importantly, LIMK2 ablation fully abrogates Aurora-A-mediated tumorigenesis in nude mice, suggesting that LIMK2 is a key oncogenic effector of Aurora A.
|
22492986 |
2012 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
LIMK2 inhibition or ablation is therefore an alternative approach for modulating Aurora A deregulation in cancer.
|
22492986 |
2012 |
|
Malignant neoplasm of urinary bladder
|
0.020 |
Biomarker
|
disease |
BEFREE |
NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation.
|
31695759 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
PCR-Restriction Fragment Length Polymorphism (RFLP) was used to genotype LIMK2 SNP rs2073859 and multivariate logistic regression applied to assess the relationship between allele frequency and clinical features in 139 BC patients.
|
30006972 |
2019 |
|
Bladder Neoplasm
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
PCR-Restriction Fragment Length Polymorphism (RFLP) was used to genotype LIMK2 SNP rs2073859 and multivariate logistic regression applied to assess the relationship between allele frequency and clinical features in 139 BC patients.
|
30006972 |
2019 |
|
Bladder Neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation.
|
31695759 |
2019 |
|
Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways.
|
30886151 |
2019 |
|
Osteosarcoma of bone
|
0.020 |
Biomarker
|
disease |
BEFREE |
Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways.
|
30886151 |
2019 |
|
Carcinoma of bladder
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
PCR-Restriction Fragment Length Polymorphism (RFLP) was used to genotype LIMK2 SNP rs2073859 and multivariate logistic regression applied to assess the relationship between allele frequency and clinical features in 139 BC patients.
|
30006972 |
2019 |
|
Carcinoma of bladder
|
0.020 |
Biomarker
|
disease |
BEFREE |
NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation.
|
31695759 |
2019 |
|
Childhood Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways.
|
30886151 |
2019 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The imbalanced expression of LIMK1 and LIMK2 is important in CRC progression, and the combined effects provide a new insight into the mechanism of CRC progression.
|
29970879 |
2018 |
|
Tumor Progression
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Reduced LIMK2 expression enhanced the nuclear accumulation of β-catenin and activated the Wnt signaling pathway, thus contributing to tumor progression.
|
29970879 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Imbalanced LIMK1 and LIMK2 expression leads to human colorectal cancer progression and metastasis via promoting β-catenin nuclear translocation.
|
29970879 |
2018 |
|
Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our study revealed that BMPR2 functions as a prometastatic oncogene <i>in vitro</i> and <i>in vivo</i> with the activation of the RhoA-ROCK-LIMK2 pathway and may represent a potential therapeutic target for osteosarcoma.
|
28938584 |
2017 |
|
Osteosarcoma of bone
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our study revealed that BMPR2 functions as a prometastatic oncogene <i>in vitro</i> and <i>in vivo</i> with the activation of the RhoA-ROCK-LIMK2 pathway and may represent a potential therapeutic target for osteosarcoma.
|
28938584 |
2017 |
|
Childhood Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our study revealed that BMPR2 functions as a prometastatic oncogene <i>in vitro</i> and <i>in vivo</i> with the activation of the RhoA-ROCK-LIMK2 pathway and may represent a potential therapeutic target for osteosarcoma.
|
28938584 |
2017 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
LIMK2 expression was reduced in intestinal tumours of cancer-prone mice, as well as in human CRC cell lines and tumours.
|
23585469 |
2014 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Reduced LIMK2 expression in colorectal cancer reflects its role in limiting stem cell proliferation.
|
23585469 |
2014 |